|
- Efficacy of Bempedoic Acid, Novel Treatment for Elevated LDL . . .
By Anthony Rice Bempedoic acid is a novel non-statin drug produced by Esperion Therapeutics to treat hypercholesterolemia, elevated levels of low-density lipoprotein (LDL) cholesterol in the blood 1 In the double-blind, placebo-controlled, phase 3 2022 CLEAR Outcomes trial conducted by Esperion, bempedoic acid treatment was associated with reductions in major adverse cardiovascular events
- Bempedoic Acid: The Statin Alternative for Lowering Cholesterol
Learn how bempedoic acid lowers cholesterol without the muscle side effects of statins See who it's for, how it works, and clinical trial results
- Comparative Cardiovascular Benefits of Bempedoic Acid and . . .
Background In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events
- Bempedoic Acid - StatPearls - NCBI Bookshelf
Bempedoic acid is a lipid-lowering agent pivotal in managing patients with elevated low-density lipoprotein cholesterol (LDL-C) levels The U S Food and Drug Administration (FDA) has sanctioned its use as an adjunct to maximally tolerated statin therapy for the reduction of LDL-C, specifically in individuals afflicted by atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial
- Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting . . .
The CLEAR Outcomes trial showed that bempedoic acid improves long-term CV outcomes and effectively reduces LDL-C compared with placebo among patients with either established ASCVD or who have a high risk for it, and with intolerance to statin therapy
- Bempedoic acid in the management of lipid disorders and . . .
Bempedoic acid, the first in-class inhibitor of ATP-citrate lyase presents a new approach to lipid-lowering therapy By reducing the endogenous production of cholesterol, upstream of the rate-limiting enzyme HMG-CoA-reductase, i e , the target of statins, bempedoic acid reduces circulating plasma concentrations of low-density lipoprotein cholesterol (LDL-C), and major adverse CVD events (MACE
- Comprehensive review of statin-intolerance and the practical . . .
Bempedoic acid (BA), an ATP citrate lyase inhibitor, decreases hepatic generation of cholesterol, upregulates low-density lipoprotein (LDL) receptor expression in the liver, and eventually clears circulating LDL-cholesterol from the blood Multiple randomized clinical trials studying BA demonstrate a reduction in LDL levels by 17–28 % in SI
- PATIENT-CENTERED EDUCATION FROM THE NATIONAL LIPID . . .
Bempedoic acid interferes with an enzyme in the liver that regulates cholesterol production It allows for increased clearance of LDL-C from the blood stream leading to lower levels Bempedoic acid is only active within the liver cells and not in skeletal muscle Therefore, it can be used in patients who have had prior statin associated muscle symptoms
|
|
|